Brinzolamide
A carbonic anhydrase inhibitor used as eye drops to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by reducing the production of aqueous humor inside the eye. It is often used in combination with other eye pressure-lowering drops.
Berat Molekul
383,5000 g/mol
LogP
-0,30
TPSA
164,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
InChI
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
Molecular Formula
C12H21N3O5S3
HBD / HBA
2 / 9
Ikatan yang Dapat Dirotasi
7
Atom Berat
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A carbonic anhydrase inhibitor used as eye drops to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by reducing the production of aqueous humor inside the eye. It is often used in combination with other eye pressure-lowering drops.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Brinzolamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL220491. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68844. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brinzolamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brinzolamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brinzolamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brinzolamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brinzolamide"></drugfyi-drug>